Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

Hoverman, M.D., Medical Director of Managed Care, US Oncology: Assessment of medication safety in the outpatient setting -- Manuel Modiano, M.D.: A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer -- Joanne Blum, M.D., Ph.D.: Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer -- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced Non-Small Cell-Lung Cancer (NSCLC) -- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the Treatment of Prostate Cancer and the Evolution of Bone Marrow Transplantation" -- Marcus Neubauer, M.D., Co-Chair: Lung Cancer Research Committee: A clinical pathways project to promote evidence-based medicine in a large community oncology practice -- Domingo Perez, M.D.: Phase II trial of carboplatin, weekly paclitaxel and biweekly bevacizumab in patients with unresectable stage IV melanoma -- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of Life (QOL) at 36 months follow-up -- Dr. Alexander Spira: Perifosine (P) an active agent in the treatment of patients with advanced sarcoma -- Dr. Alexander Spira: iTARGET: A Phase II Trial to Assess the Response to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell-Lung Cancer (NSCLC) Tumors -- Dr. Hakan Kaya: Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis -- Dr. Hakan Kaya:
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Acsis Inc., ... protection and serialization solutions, has recently posted an ... that addresses current and future needs for companies, ... the old supply chain model no longer work ... technology, including the growth of mobile technology, machine ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2
... WIRE)--Jun 19, 2007 - Javelin,Pharmaceuticals (AMEX: JAV) ... morphine) successfully met its,primary clinical endpoint, the ... over 0-24 hours postoperatively. In this first ... moderate-to-severe pain,after elective orthopedic surgery were given ...
... --,Nuvelo, Inc. today announced the publication of the ... rNAPc2,To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) ... of Cardiology (JACC), demonstrating,that higher-dose (greater than or ... (rNAPc2) reduced the incidence,and duration of ischemia as ...
Cached Medicine Technology:Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 2Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 3Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 4Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4
(Date:7/25/2014)... Phoenix, AZ (PRWEB) July 25, 2014 ... firm offering discount attorney’s fees with regard to ... Hastings provide a wide range of legal services ... of the negligence of another individual or corporation. Free ... of determining the validity of a potential personal ...
(Date:7/25/2014)... for lymphoma may lower men,s fertility, new research indicates. ... cancers of the body,s white blood cells, often affect ... For men, treatment for these cancers can harm or ... within two years of treatment, the researchers cautioned that ... significant side effect before treatment begins. "While many ...
(Date:7/25/2014)... 2014 Parkulture is proud ... and parkour instructor, Jared “JJ” Woods, will be competing ... American Ninja Warrior. The show will premiere on local ... will rerun on the new Esquire Network on Tuesday, ... resident, has been balancing careers as a professional stuntman ...
(Date:7/25/2014)... The Rottenstein Law Group LLP, ... 25 years of experience advocating for plaintiffs with ... announces the launch of its new website, ... believe they have been harmed by the prescription ... information about the severe adverse side effects allegedly ...
(Date:7/25/2014)... Twins, genes may play a greater role in language ... Researchers found more evidence that language traits, ... largely inherited. The study involving 473 sets of ... of language performance for twins than single-born children) was ... finding disputes hypotheses that attribute delays in early language ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Genes May Be Key to Language Delay in Kids 2
... is very rare, affecting approximately one in every 100,000 ... i.e. they are born with empty eye sockets. This ... in the normal way in the first 28 days ... fitted with prosthetic eyes to allow normal facial// development. ...
... which occurs when the heart becomes so enlarged that it ... affects 35 in every 100,000 people. Researchers in the United ... journal Science that a defect in the gene phospholamban may ... the flow of calcium through the heart, enabling it to ...
... using a new imaging technique based on Magnetic Resonance ... now, MRI was used to show how Alzheimer's disease ... for memory and learning. And post-mortem studies revealed how ... the first time a three-dimensional time lapse video of ...
... by scientists at the Johns Hopkins School of Public Health ... have called for urgent research into the impact of soya ... chemical in soya can damage the male reproductive organs. Though ... effect on humans, its effects on rats were so severe ...
... published in the February issue of the British Medical Journal ... more at risk of heart disease later in life than ... live infant in Scotland during the years 1981-85, were identified ... miscarriage or repeated miscarriages. Then, during 1981 to 1999, the ...
... blood has been believed to be the most ... heart disease is associated with increased levels of ... LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) or ... researchers in Canada and Sweden are now putting ...
Cached Medicine News:Health News:Miscarriage during pregnancy and heart disease linked 2
... designed for low to medium throughput reading of ... from one to three racks and reads in ... are exported via text files and a list ... integration with other programs. System includes a USB ...
... steel work surface. Pneumatic ... to protect operator, as ... equipment from the workstation. ... for multiple vibration-free work ...
... top with powder-coated steel legs. ... Available in hundreds of sizes ... drawers, light fixtures and ionizing ... in custom building to meet ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
Medicine Products: